SwRI-developed bioreactor replicates versatile induced Pluripotent Stem Cells

Reprogrammed adult cells offer alternative to embryonic stem cell

2025-11-10

(Press-News.org) SAN ANTONIO — November 10, 2025 — Southwest Research Institute (SwRI) has demonstrated a new application for its cell-expansion bioreactor to advance tissue engineering and cell-based therapies for treatment of injuries and diseases.

SwRI scientists used the bioreactor to replicate induced Pluripotent Stem Cells (iPSCs) derived from adult skin, blood, and other somatic cells. Their pluripotent state allows iPSCs to differentiate into any other cell type in the body, much like embryonic stem cells but without the same ethical ambiguity. Large quantities of iPSCs are needed for regenerative medicine and individualized healthcare, but current technology requires manual production.

“Using the SwRI-developed single-use 3D-printed bioreactor, we successfully harvested significant quantities of iPSCs,” said Senior Research Scientist Dr. Nick Mc Mahon, the leader on the project. “We are working on further differentiating those iPSCs into neural progenitor cells, which could support the regeneration of neurons that are damaged due to injury. International studies have shown that neural progenitor cells can repair the spinal cord when administered in the first 28 days following a spinal cord injury.”

SwRI’s 3D printed bioreactor matrix boasts a larger surface-to-volume ratio compared to traditional 2D cell culture devices such as flasks or dishes, and it can grow more cells using an automated perfusion method. Due to the exceptional geometry of SwRI’s bioreactor, cells maintain a monolayer without forming clusters during the cultivation process, minimizing the risk of spontaneous differentiation into the wrong type of cells.

“Since the discovery of iPSCs in the early 2000s, scientists have been exploring their potential to revolutionize medicine by using a patient’s own cells to repair or replace damaged tissues to avoid immune rejection. Unlike embryonic stem cells, iPSCs pose no ethical controversy, making them a promising and responsible path toward personalized medicine,” said Institute Engineer Dr. Jian Ling.

SwRI plans to further refine the prototype to advance automation and provide a simplified plug-and-play cell replication platform to accelerate the development of iPSC-based therapies.

This project received funding through SwRI’s Internal Research and Development Program. In 2024, SwRI invested more than $11 million in tomorrow’s technology to broaden its knowledge base, expand its reputation as a leader in science and technology and encourage its staff’s professional development. To learn more, visit: Southwest Research Institute Internal R&D.

SwRI’s Pharmaceutical and Bioengineering Department advances new pharmaceutical research, custom assays and biomedical devices. SwRI staff will present at the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 November 9-12 in San Antonio.

To learn more, visit https://www.swri.org/markets/biomedical-health/biomedical-devices/materials-bioengineering/cell-gene-therapy-cgt-research.

END

ELSE PRESS RELEASES FROM THIS DATE:

Trial showing ivermectin safety in small children could spur progress against several neglected tropical diseases

2025-11-10

Trial Showing Ivermectin Safety in Small Children Could Spur Progress Against Several Neglected Tropical Diseases TORONTO (November 10, 2025)—Millions of very young children currently excluded from treatment with the drug ivermectin could be safely included in ongoing campaigns against challenging and often neglected tropical diseases such as intestinal worms, scabies and river blindness, according to results from a clinical trial presented today at the Annual Meeting of the American Society ...

Human approach is hypothesized to be superior to technology for supportive cancer care according to new data in JNCCN

2025-11-10

PLYMOUTH MEETING, PA [November 10, 2025] — New research in the November 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network explores the perceptions regarding the effectiveness of team-based and technology-based approaches for supportive care for people with cancer. The ongoing supportive care study includes discussions on patient goals, values, and preferences, in addition to symptom management. According to the results from this mixed-methods study, 87.5% of team-based clinic participants perceived that method is more ...

Mount Sinai’s Jean-Frédéric Colombel, MD, to deliver the 31st Anatomy Lesson in Amsterdam, highlighting global efforts to prevent and cure Crohn’s disease

2025-11-10

New York, NY (November 10 2025) — In a high honor, Jean-Frédéric Colombel, MD, a leading inflammatory bowel disease (IBD) expert at the Icahn School of Medicine at Mount Sinai, will deliver the 31st Anatomy Lesson on Thursday, November 20, at the Concertgebouw in Amsterdam. His lecture, “Tackling the Growing Problem of Immune Diseases—Crohn’s Disease as an Example,” will explore Mount Sinai’s pioneering work in the early detection, prevention, and treatment of IBD. The Anatomy Lesson, an annual public lecture organized by Amsterdam UMC, invites leading international physicians and researchers to reflect on medicine’s ...

Breast cancer case study could inform clinical trials

2025-11-10

When researchers look for potential cancer therapy targets, they typically go after protein-coding genes that participate in disease progression. Disrupt them and negate whatever role they play in cancer’s development or spread. Researchers at Cold Spring Harbor Laboratory (CSHL) have also been working on another kind of target. They’re studying a long non-coding RNA called MALAT1. So far, it’s been linked to more than 20 different types of tumors. In a new and unique study published in Molecular Therapy: Oncology, CSHL researchers track MALAT1 levels ...

Cherie Zachary, MD, installed as ACAAI President

2025-11-10

ORLANDO (NOV. 9, 2025) – Allergist Cherie Zachary, MD, of Bloomington, MN was installed as president of the American College of Allergy, Asthma and Immunology (ACAAI) at the ACAAI Annual Scientific Meeting on November 10 in Orlando. Allergist David Stukus, MD, of Columbus, OH, was elected ACAAI president-elect. Other newly-elected ACAAI officers are Maureen Petersen, MD, of Clayton, NC, as vice president and Melinda Rathkopf, MD, MBA, of Atlanta, GA, as treasurer. Regents elected for three-year terms include Christopher C. Chang, MD, PhD, MBA, Hollywood, Florida, Mitchell H. Grayson, MD, Columbus, OH, and Jay A. Lieberman, ...

Billions live in environments that violate human rights

2025-11-10

More than 99% of the world’s 7.7 billion people have one or more of their environmental rights threatened, according to new research. In the most comprehensive analysis of inequality in environmental conditions to date, CU Boulder researchers revealed that nearly half of the global population lives in regions facing three or more environmental problems. Those include polluted air, unsafe water, extreme heat, food insecurity and biodiversity loss. The analysis was published September 25 in Environmental Research Communications. It provides strong ...

Thyroid gland new possible target for prostate cancer treatment

2025-11-10

A hormone produced in the thyroid gland can play a key role in the development of prostate cancer. This is shown in a new study by an international research group led by Umeå University, Sweden, and the Medical University of Vienna, Austria. By blocking a receptor for the hormone, the growth of tumour cells in the prostate was inhibited. In the long term, the discovery may open up a new way of attacking certain types of aggressive prostate cancer. "The results indicate that the receptor in question is a driving force in the growth of cancer. Substances that block it could thus be a target for future drugs against prostate cancer," ...

New study reveals devastating impact of cane toads approaching the Pilbara

2025-11-10

New Curtin University research has found invasive cane toads are on track to reach Western Australia’s Pilbara region within the next 10 to 20 years, threatening to cause widespread losses among native species and significant cultural and economic harm. The study, published in Scientific Reports, predicts that without containment efforts, the toxic amphibians will colonise up to 75 per cent of the Pilbara within three decades, putting 25 native species at risk of serious population declines. These include several species of native marsupial predators like northern quolls, ghost bat and kaluta, as well as frog-eating snakes, blue-tongue skinks and goannas. Of ...

COP30: Global nature goals at risk as conservation projects quietly fail

2025-11-10

As world leaders begin COP30 climate negotiations in Brazil this week, an international team co-led by a University of Sydney researcher has warned of a hidden crisis undermining global biodiversity and carbon targets: the quiet abandonment of conservation projects. The comment paper, ‘Conservation abandonment is a policy blind spot’, published in Nature Ecology & Evolution, was co-led by Dr Matthew Clark, a postdoctoral researcher in the Thriving Oceans Research Hub at the University of Sydney and an honorary research associate in the Centre for Environmental Policy at Imperial College ...

New treatment for combating iron deficiency more effectively

2025-11-10

Iron deficiency is globally widespread. Women are particularly affected, with one in five in Europe suffering from iron deficiency. The consequences are anaemia, constant fatigue, chronic headaches and a weakened immune system. Researchers led by ETH professor Raffaele Mezzenga have now developed a new dietary supplement that could efficiently treat iron deficiency and anaemia. This development is being co-led by Michael B. Zimmermann, professor emeritus at ETH Zurich. The preparation consists of edible oat protein ...

SwRI-developed bioreactor replicates versatile induced Pluripotent Stem Cells

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: